Exelixis (EXEL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
17 Apr, 2026Voting matters and shareholder proposals
Clarifies the voting standard for Proposal No. 3 regarding the Amended 2017 Plan, requiring a majority of shares present or represented by proxy and entitled to vote for approval.
Abstentions will count as votes against Proposal No. 3, while broker non-votes will have no effect on the outcome.
Board of directors and corporate governance
The Board of Directors is soliciting proxies for the 2026 Annual Meeting scheduled for May 26, 2026.
Shareholder rights and capital structure
Shareholders may change or revoke their prior votes by following instructions provided in the proxy materials.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Exelixis
- Disciplined franchise-building in GU/GI oncology drives innovation, growth, and pan-tumor leadership.EXEL
Bernstein 42nd Annual Strategic Decisions Conference27 May 2026 - All proposals passed, directors elected, and no stockholder questions were raised.EXEL
AGM 202627 May 2026 - Zanzalintinib targets leadership in CRC and RCC with pivotal trials and robust clinical strategy.EXEL
Stifel 2026 Targeted Oncology Virtual Forum20 May 2026 - CABO and zanza drive growth with strong launches, pivotal trials, and robust commercial execution.EXEL
RBC Capital Markets Global Healthcare Conference 202619 May 2026 - Zanzalintinib and CABOMETYX fuel growth as new studies and pipeline assets target solid tumors.EXEL
Barclays 28th Annual Global Healthcare Conference17 May 2026 - Flexible capital deployment supports CABO and zanza growth, with major trials and launches ahead.EXEL
Bank of America Global Healthcare Conference 202612 May 2026 - Q1 2026 saw 10% revenue growth, strong cabozantinib sales, and zanzalintinib NDA progress.EXEL
Q1 20266 May 2026 - Zanzalintinib advances as a next-gen TKI amid strong growth and expanding oncology pipeline.EXEL
TD Cowen 46th Annual Health Care Conference29 Apr 2026 - Shareholders to vote on directors, auditor, equity plan, and pay amid strong growth and ESG focus.EXEL
Proxy filing15 Apr 2026